Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2008

ZaBeCor Forms Subsidiary that Will Concentrate on siRNA Cancer Therapies

  • ZaBeCor Pharmaceuticals has formed a subsidiary, Biothorpe Pharmaceuticals, to focus on the development of siRNA, antisense, and other molecular technologies for cancer treatment. Biothorpe's intellectual property (IP) portfolio includes the therapeutic use of siRNA and other oligonucleotides directed at Syk kinase, which is required for the proliferation of malignant cells in several cancers, according to some studies.

    The company intends to license its IP for the treatment of three cancers: acute myelogenous leukemia, B-cell lymphoma, and chronic lymphocytic leukemia. Biothorpe's IP is based upon research conducted at the University of Pennsylvania School of Medicine.

    “ZaBeCor will continue to focus on inflammatory disorders, particularly on developing our anti-inflammatory drug candidate Excellair™, while Biothorpe builds upon the groundbreaking research of applying siRNA technology toward malignant cells in the blood and lymphatic system.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »